- What happened: CM Hospitalar (Viveo) has concluded the subscription period for leftover shares from its capital increase.
- The figures: 99.71% of the maximum amount was subscribed, totaling R$ 867.2 million.
- The price: The new shares were priced at R$ 0.90, while on the exchange, VVEO3 stock fell to R$ 0.63.
VVEO3 shares have not disappeared from brokerage accounts, but they are undergoing severe dilution that explains the 14.8% drop in the latest trading session. The conclusion of the capital increase brings nearly 1 billion new shares to the market.
What Happened to VVEO3 Shares?
VVEO3 shares (CM Hospitalar) closed the subscription period for leftover shares from their capital increase with a 99.71% uptake of the maximum amount. According to the notice to shareholders filed with Brazil's securities commission, the CVM, on 10/27/2026, the company raised a preliminary R$ 867.2 million through the issuance of 963.5 million new common shares.
The market reacted with heavy pessimism: on the day of the announcement, the stock tumbled 14.86%, closing at R$ 0.63. This movement alarms investors because the price set for the new shares in the capital increase was R$ 0.90. When a company issues shares at a price very different from what the market is willing to pay on the screen, the adjustment tends to be painful for existing position holders.
CM Hospitalar reported that following the preference and leftover periods, only 2.8 million unsubscribed shares remained (0.29% of the total). Because the uptake was nearly total, the company decided that there will be no auction of leftover shares, and these remaining shares simply will not be issued.
Why Did VVEO3 Fall So Much and "Disappear" for Some Investors?
If you cannot sell your shares or see an unfamiliar balance in your brokerage account, the reason is the processing of the subscription. The new shares subscribed at R$ 0.90 are not yet available for trading; they appear as a receipt (usually VVEO1 or VVEO2) until the process is officially approved.
The 14.86% drop reflects two main factors:
- Massive Dilution: The company is issuing nearly 1 billion new shares. Investors who did not put in more money to participate in the capital increase saw their stake in the company shrink proportionally.
- Arbitrage and Risk: The fact that BTG Pactual subscribed to leftover shares to fulfill a prior commitment and the possibility of paying for the shares with debenture credits rather than cash signals that part of this capital increase is a debt-for-equity swap, which the market does not always read as organic growth.
Price set for the new shares.
Current quotation after the drop.
Volume entering the market.
Another point generating confusion is the capitalization of credits. CM Hospitalar's filing clarifies that some subscribers used debenture credits to pay for the new shares. This means the company is not necessarily receiving R$ 867 million in fresh cash, but rather reducing its debt by turning creditors into shareholders.
Timeline: When Do the New VVEO3 Shares Appear?
Investors who participated in the leftover subscription or are waiting for the market to stabilize should pay attention to the dates estimated by the company. The process still depends on approval by the Board of Directors.
Itaú Corretora, serving as the bookkeeping agent, and the B3 will inform each subscriber of the exact number of shares allocated. Until then, the stock price may remain volatile as the market attempts to price the company's real value with this new volume of shares in circulation.
If you are a VVEO3 shareholder and did not participate in the capital increase, your stake has been diluted. The per-share value of your investment has changed. If you did participate, you paid R$ 0.90 for something currently valued at R$ 0.63 on the secondary market—an immediate unrealized loss that will only be reversed if Viveo's turnaround thesis proves correct over the long term.
Is It Worth Holding VVEO3 After the Capital Increase?
The quality rating for VVEO3 from Rico aos Poucos is 3.1 out of 10, placing the company in a high-risk zone. The 53% drop over the past 12 months reflects operational difficulties and the leverage that forced this capital increase.
The entry of BTG Pactual as a subscriber for leftover shares ensures the transaction will be completed, but it does not guarantee that the stock price will rise. On the contrary, the conversion of debt into equity often triggers future forced selling by creditors who have no interest in being long-term partners, but simply want to recover their credit.
Approval Notice — Verify whether the final amount and share count were adjusted on 10/30.
Receipt Conversion — Check with your brokerage around 11/03 to see the receipts turn into VVEO3 shares.
Next Quarterly Results — Monitor whether the debt reduction via capitalization improves net income.
